Treatment of acute vascular rejection with immunoadsorption

Maria Teresa Olivari, Camille B. May, Nancy A. Johnson, W. Steves Ring, Michael K. Stephens

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Acute vascular rejection (AVR) is characterized by vascular injury and systolic graft dysfunction and is often associated with elevated panel reactive antibodies (PRAs) to HLA antigens. Plasmapheresis has been shown to improve the otherwise poor prognosis of AVR, but its use is often complicated and limited by hypotension. Methods and Results: In three cardiac transplant recipients with severe hemodynamic compromise during AVR, refractory to standard therapy, extracorporeal immunoadsorption was performed using a protein A column. Plasma was removed at 10 to 20 cm3/min, passed through the column, and reinfused. All three patients had negative pretransplant PRAs. PRA rose before or during AVR and became negative in all three patients following immunoadsorption. Time course and number of treatments required to decrease PRA to <5% varied. Concomitant with a decrease in PRA, histological findings and ventricular function improved and normalized. Ejection fraction rose from 23±2 to 56±8% and shortening fraction from 14±7 to 36±7%, P<.05 (both). One patient died from infection 2 months after resolution of AVR; the other two patients are alive 25 and 31 months after AVR with normal left ventricular function and coronary arteries. In both, since initial immunoadsorption course, PRA has remained negative and no rejection has occurred. In two patients, a circulating donor-specific or donor-related anti-HLA class I antibody was identified and removed by protein A column. Conclusions: Our preliminary data suggest that (1) immunoadsorption is effective in removing circulating immunoglobulins and is well tolerated; (2) AVR is preceded by or associated with circulating antibodies against HLA class I antigens; (3) their removal is temporarily associated with recovery of graft function and normalization of biopsy; and (4) anti-HLA class I antibodies can mediate vascular injury if they appear in the post-transplant period.

Original languageEnglish (US)
JournalCirculation
Volume90
Issue number5 II
StatePublished - Nov 1994

Fingerprint

Blood Vessels
Antibodies
Immunoglobulin Isotypes
Vascular System Injuries
Staphylococcal Protein A
HLA Antigens
Transplants
Therapeutics
Tissue Donors
Histocompatibility Antigens Class I
Plasmapheresis
Ventricular Function
Recovery of Function
Left Ventricular Function
Hypotension
Immunoglobulins
Coronary Vessels
Hemodynamics
Biopsy
Infection

Keywords

  • antibodies
  • cardiac transplantation
  • immunoadsorption

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Olivari, M. T., May, C. B., Johnson, N. A., Ring, W. S., & Stephens, M. K. (1994). Treatment of acute vascular rejection with immunoadsorption. Circulation, 90(5 II).

Treatment of acute vascular rejection with immunoadsorption. / Olivari, Maria Teresa; May, Camille B.; Johnson, Nancy A.; Ring, W. Steves; Stephens, Michael K.

In: Circulation, Vol. 90, No. 5 II, 11.1994.

Research output: Contribution to journalArticle

Olivari, MT, May, CB, Johnson, NA, Ring, WS & Stephens, MK 1994, 'Treatment of acute vascular rejection with immunoadsorption', Circulation, vol. 90, no. 5 II.
Olivari MT, May CB, Johnson NA, Ring WS, Stephens MK. Treatment of acute vascular rejection with immunoadsorption. Circulation. 1994 Nov;90(5 II).
Olivari, Maria Teresa ; May, Camille B. ; Johnson, Nancy A. ; Ring, W. Steves ; Stephens, Michael K. / Treatment of acute vascular rejection with immunoadsorption. In: Circulation. 1994 ; Vol. 90, No. 5 II.
@article{70199c9106714508b1eb34a989767343,
title = "Treatment of acute vascular rejection with immunoadsorption",
abstract = "Background: Acute vascular rejection (AVR) is characterized by vascular injury and systolic graft dysfunction and is often associated with elevated panel reactive antibodies (PRAs) to HLA antigens. Plasmapheresis has been shown to improve the otherwise poor prognosis of AVR, but its use is often complicated and limited by hypotension. Methods and Results: In three cardiac transplant recipients with severe hemodynamic compromise during AVR, refractory to standard therapy, extracorporeal immunoadsorption was performed using a protein A column. Plasma was removed at 10 to 20 cm3/min, passed through the column, and reinfused. All three patients had negative pretransplant PRAs. PRA rose before or during AVR and became negative in all three patients following immunoadsorption. Time course and number of treatments required to decrease PRA to <5{\%} varied. Concomitant with a decrease in PRA, histological findings and ventricular function improved and normalized. Ejection fraction rose from 23±2 to 56±8{\%} and shortening fraction from 14±7 to 36±7{\%}, P<.05 (both). One patient died from infection 2 months after resolution of AVR; the other two patients are alive 25 and 31 months after AVR with normal left ventricular function and coronary arteries. In both, since initial immunoadsorption course, PRA has remained negative and no rejection has occurred. In two patients, a circulating donor-specific or donor-related anti-HLA class I antibody was identified and removed by protein A column. Conclusions: Our preliminary data suggest that (1) immunoadsorption is effective in removing circulating immunoglobulins and is well tolerated; (2) AVR is preceded by or associated with circulating antibodies against HLA class I antigens; (3) their removal is temporarily associated with recovery of graft function and normalization of biopsy; and (4) anti-HLA class I antibodies can mediate vascular injury if they appear in the post-transplant period.",
keywords = "antibodies, cardiac transplantation, immunoadsorption",
author = "Olivari, {Maria Teresa} and May, {Camille B.} and Johnson, {Nancy A.} and Ring, {W. Steves} and Stephens, {Michael K.}",
year = "1994",
month = "11",
language = "English (US)",
volume = "90",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5 II",

}

TY - JOUR

T1 - Treatment of acute vascular rejection with immunoadsorption

AU - Olivari, Maria Teresa

AU - May, Camille B.

AU - Johnson, Nancy A.

AU - Ring, W. Steves

AU - Stephens, Michael K.

PY - 1994/11

Y1 - 1994/11

N2 - Background: Acute vascular rejection (AVR) is characterized by vascular injury and systolic graft dysfunction and is often associated with elevated panel reactive antibodies (PRAs) to HLA antigens. Plasmapheresis has been shown to improve the otherwise poor prognosis of AVR, but its use is often complicated and limited by hypotension. Methods and Results: In three cardiac transplant recipients with severe hemodynamic compromise during AVR, refractory to standard therapy, extracorporeal immunoadsorption was performed using a protein A column. Plasma was removed at 10 to 20 cm3/min, passed through the column, and reinfused. All three patients had negative pretransplant PRAs. PRA rose before or during AVR and became negative in all three patients following immunoadsorption. Time course and number of treatments required to decrease PRA to <5% varied. Concomitant with a decrease in PRA, histological findings and ventricular function improved and normalized. Ejection fraction rose from 23±2 to 56±8% and shortening fraction from 14±7 to 36±7%, P<.05 (both). One patient died from infection 2 months after resolution of AVR; the other two patients are alive 25 and 31 months after AVR with normal left ventricular function and coronary arteries. In both, since initial immunoadsorption course, PRA has remained negative and no rejection has occurred. In two patients, a circulating donor-specific or donor-related anti-HLA class I antibody was identified and removed by protein A column. Conclusions: Our preliminary data suggest that (1) immunoadsorption is effective in removing circulating immunoglobulins and is well tolerated; (2) AVR is preceded by or associated with circulating antibodies against HLA class I antigens; (3) their removal is temporarily associated with recovery of graft function and normalization of biopsy; and (4) anti-HLA class I antibodies can mediate vascular injury if they appear in the post-transplant period.

AB - Background: Acute vascular rejection (AVR) is characterized by vascular injury and systolic graft dysfunction and is often associated with elevated panel reactive antibodies (PRAs) to HLA antigens. Plasmapheresis has been shown to improve the otherwise poor prognosis of AVR, but its use is often complicated and limited by hypotension. Methods and Results: In three cardiac transplant recipients with severe hemodynamic compromise during AVR, refractory to standard therapy, extracorporeal immunoadsorption was performed using a protein A column. Plasma was removed at 10 to 20 cm3/min, passed through the column, and reinfused. All three patients had negative pretransplant PRAs. PRA rose before or during AVR and became negative in all three patients following immunoadsorption. Time course and number of treatments required to decrease PRA to <5% varied. Concomitant with a decrease in PRA, histological findings and ventricular function improved and normalized. Ejection fraction rose from 23±2 to 56±8% and shortening fraction from 14±7 to 36±7%, P<.05 (both). One patient died from infection 2 months after resolution of AVR; the other two patients are alive 25 and 31 months after AVR with normal left ventricular function and coronary arteries. In both, since initial immunoadsorption course, PRA has remained negative and no rejection has occurred. In two patients, a circulating donor-specific or donor-related anti-HLA class I antibody was identified and removed by protein A column. Conclusions: Our preliminary data suggest that (1) immunoadsorption is effective in removing circulating immunoglobulins and is well tolerated; (2) AVR is preceded by or associated with circulating antibodies against HLA class I antigens; (3) their removal is temporarily associated with recovery of graft function and normalization of biopsy; and (4) anti-HLA class I antibodies can mediate vascular injury if they appear in the post-transplant period.

KW - antibodies

KW - cardiac transplantation

KW - immunoadsorption

UR - http://www.scopus.com/inward/record.url?scp=0027948344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027948344&partnerID=8YFLogxK

M3 - Article

C2 - 7955287

AN - SCOPUS:0027948344

VL - 90

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5 II

ER -